Silence Therapeutics PLC (SLN) — Capital Reinvestment Ratio
Silence Therapeutics PLC (SLN) has a Capital Reinvestment Ratio of 0.02x as of June 2021, meaning it reinvests 0% of its operating cash flow ($26.03 Million) in capital expenditures ($439.00K). See SLN net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Silence Therapeutics PLC Capital Reinvestment Ratio (2019–2021)
This chart tracks Silence Therapeutics PLC's Capital Reinvestment Ratio across 2 annual periods. Check total reinvestment intensity of Silence Therapeutics PLC to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Silence Therapeutics PLC (2019–2021)
Year-by-year Capital Reinvestment Ratio for Silence Therapeutics PLC from 2019 to 2021. For live market cap and broader valuation context, see Silence Therapeutics PLC market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.20x | $9.19 Million | $1.80 Million | ▲ +3661.1% |
| 2019 | 0.01x | $1.73 Million | $9.00K | — |